25 XP   0   0   10

Hubei Jumpcan Pharmaceutical Co Ltd
Buy, Hold or Sell?

Let's analyse Jumpcan together

PenkeI guess you are interested in Hubei Jumpcan Pharmaceutical Co Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Hubei Jumpcan Pharmaceutical Co Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Hubei Jumpcan Pharmaceutical Co Ltd

I send you an email if I find something interesting about Hubei Jumpcan Pharmaceutical Co Ltd.

Quick analysis of Jumpcan (30 sec.)










What can you expect buying and holding a share of Jumpcan? (30 sec.)

How much money do you get?

How much money do you get?
¥0.12
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
¥14.50
Expected worth in 1 year
¥16.69
How sure are you?
97.5%

+ What do you gain per year?

Total Gains per Share
¥3.08
Return On Investment
7.7%

For what price can you sell your share?

Current Price per Share
¥40.15
Expected price per share
¥34.50 - ¥45.18
How sure are you?
50%

1. Valuation of Jumpcan (5 min.)




Live pricePrice per Share (EOD)

¥40.15

Intrinsic Value Per Share

¥20.82 - ¥39.30

Total Value Per Share

¥35.32 - ¥53.80

2. Growth of Jumpcan (5 min.)




Is Jumpcan growing?

Current yearPrevious yearGrowGrow %
How rich?$1.8b$1.4b$312.3m18.2%

How much money is Jumpcan making?

Current yearPrevious yearGrowGrow %
Making money$97.3m$74.8m$22.4m23.1%
Net Profit Margin29.4%24.9%--

How much money comes from the company's main activities?

3. Financial Health of Jumpcan (5 min.)




What can you expect buying and holding a share of Jumpcan? (5 min.)

Welcome investor! Jumpcan's management wants to use your money to grow the business. In return you get a share of Jumpcan.

What can you expect buying and holding a share of Jumpcan?

First you should know what it really means to hold a share of Jumpcan. And how you can make/lose money.

Speculation

The Price per Share of Jumpcan is ¥40.15. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Jumpcan.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Jumpcan, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ¥14.50. Based on the TTM, the Book Value Change Per Share is ¥0.55 per quarter. Based on the YOY, the Book Value Change Per Share is ¥0.60 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ¥0.22 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Jumpcan.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share
Usd Eps0.130.3%0.110.3%0.080.2%0.070.2%0.050.1%
Usd Book Value Change Per Share0.130.3%0.080.2%0.080.2%0.060.1%0.050.1%
Usd Dividend Per Share0.000.0%0.030.1%0.020.1%0.030.1%0.030.1%
Usd Total Gains Per Share0.130.3%0.110.3%0.110.3%0.090.2%0.080.2%
Usd Price Per Share4.34-4.01-3.57-3.52-3.89-
Price to Earnings Ratio8.24-9.62-11.21-13.29-21.86-
Price-to-Total Gains Ratio32.28-63.56-39.04-53.62-57.46-
Price to Book Ratio2.17-2.15-2.35-2.89-5.81-
Price-to-Total Gains Ratio32.28-63.56-39.04-53.62-57.46-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share5.5407
Number of shares180
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.030.03
Usd Book Value Change Per Share0.080.06
Usd Total Gains Per Share0.110.09
Gains per Quarter (180 shares)19.1315.85
Gains per Year (180 shares)76.5163.40
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1225467214353
2441091444285116
36716322162128179
48921729883171242
5111272375104213305
6133326452125256368
7155380529145298431
8177435606166341494
9200489683187384557
10222543760208426620

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%40.00.00.0100.0%83.00.05.094.3%
Book Value Change Per Share3.01.00.075.0%10.02.00.083.3%16.04.00.080.0%33.07.00.082.5%73.015.00.083.0%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%40.00.00.0100.0%83.00.05.094.3%
Total Gains per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%39.01.00.097.5%85.03.00.096.6%

Fundamentals of Jumpcan

About Hubei Jumpcan Pharmaceutical Co Ltd

Hubei Jumpcan Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, and trading of Chinese traditional medicines, western medicines, daily use chemical based Chinese traditional medicines, and Chinese medicine health products in China. The company offers Chinese and western medicines in the areas of pediatrics, gynecology, pneumology, gastroenterology, and geriatrics; oral and skin care products; and anti-fatigue, anti-aging, antioxidant, and immunity-enhancing Chinese medicine health products. It also develops Chinese and western medicines in the areas of detoxification, digestive system, respiratory system, nervous system, anti-infection, cardiovascular, narcotic analgesic, nutrition, musculoskeletal, and hemostasis. The company was formerly known as Hubei Hongcheng General Machinery Co., Ltd and changed its name to Hubei Jumpcan Pharmaceutical Co., Ltd. in March 2015. Hubei Jumpcan Pharmaceutical Co., Ltd. is based in Taixing, China.

Fundamental data was last updated by Penke on 2024-04-17 08:44:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Hubei Jumpcan Pharmaceutical Co Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Jumpcan earns for each ¥1 of revenue.

  • Above 10% is considered healthy but always compare Jumpcan to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 28.2% means that ¥0.28 for each ¥1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Hubei Jumpcan Pharmaceutical Co Ltd:

  • The MRQ is 28.2%. The company is making a huge profit. +2
  • The TTM is 29.4%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ28.2%TTM29.4%-1.3%
TTM29.4%YOY24.9%+4.6%
TTM29.4%5Y24.2%+5.2%
5Y24.2%10Y22.2%+2.0%
1.1.2. Return on Assets

Shows how efficient Jumpcan is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Jumpcan to the Drug Manufacturers - Specialty & Generic industry mean.
  • 4.8% Return on Assets means that Jumpcan generated ¥0.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Hubei Jumpcan Pharmaceutical Co Ltd:

  • The MRQ is 4.8%. Using its assets, the company is less efficient in making profit.
  • The TTM is 4.2%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ4.8%TTM4.2%+0.6%
TTM4.2%YOY4.0%+0.2%
TTM4.2%5Y4.0%+0.2%
5Y4.0%10Y4.6%-0.5%
1.1.3. Return on Equity

Shows how efficient Jumpcan is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Jumpcan to the Drug Manufacturers - Specialty & Generic industry mean.
  • 6.6% Return on Equity means Jumpcan generated ¥0.07 for each ¥1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Hubei Jumpcan Pharmaceutical Co Ltd:

  • The MRQ is 6.6%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 5.7%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ6.6%TTM5.7%+0.9%
TTM5.7%YOY5.3%+0.3%
TTM5.7%5Y5.5%+0.1%
5Y5.5%10Y6.4%-0.9%

1.2. Operating Efficiency of Hubei Jumpcan Pharmaceutical Co Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Jumpcan is operating .

  • Measures how much profit Jumpcan makes for each ¥1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Jumpcan to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ¥0.00  for each ¥1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Hubei Jumpcan Pharmaceutical Co Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM14.6%-14.6%
TTM14.6%YOY25.7%-11.1%
TTM14.6%5Y22.7%-8.1%
5Y22.7%10Y13.3%+9.4%
1.2.2. Operating Ratio

Measures how efficient Jumpcan is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.87 means that the operating costs are ¥0.87 for each ¥1 in net sales.

Let's take a look of the Operating Ratio trends of Hubei Jumpcan Pharmaceutical Co Ltd:

  • The MRQ is 0.874. The company is less efficient in keeping operating costs low.
  • The TTM is 0.884. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.874TTM0.884-0.011
TTM0.884YOY0.910-0.026
TTM0.8845Y0.919-0.035
5Y0.91910Y0.581+0.338

1.3. Liquidity of Hubei Jumpcan Pharmaceutical Co Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Jumpcan is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 3.10 means the company has ¥3.10 in assets for each ¥1 in short-term debts.

Let's take a look of the Current Ratio trends of Hubei Jumpcan Pharmaceutical Co Ltd:

  • The MRQ is 3.100. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.178. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.100TTM3.178-0.078
TTM3.178YOY3.141+0.037
TTM3.1785Y3.038+0.140
5Y3.03810Y1.697+1.342
1.3.2. Quick Ratio

Measures if Jumpcan is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Jumpcan to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.29 means the company can pay off ¥1.29 for each ¥1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Hubei Jumpcan Pharmaceutical Co Ltd:

  • The MRQ is 1.286. The company is able to pay all its short-term debts with the most liquid assets. +1
  • The TTM is 1.109. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.286TTM1.109+0.177
TTM1.109YOY1.904-0.795
TTM1.1095Y1.380-0.271
5Y1.38010Y1.290+0.090

1.4. Solvency of Hubei Jumpcan Pharmaceutical Co Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Jumpcan assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Jumpcan to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.26 means that Jumpcan assets are financed with 26.3% credit (debt) and the remaining percentage (100% - 26.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Hubei Jumpcan Pharmaceutical Co Ltd:

  • The MRQ is 0.263. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.256. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.263TTM0.256+0.008
TTM0.256YOY0.241+0.014
TTM0.2565Y0.268-0.013
5Y0.26810Y0.282-0.014
1.4.2. Debt to Equity Ratio

Measures if Jumpcan is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Jumpcan to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 35.8% means that company has ¥0.36 debt for each ¥1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Hubei Jumpcan Pharmaceutical Co Ltd:

  • The MRQ is 0.358. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.344. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.358TTM0.344+0.013
TTM0.344YOY0.319+0.026
TTM0.3445Y0.369-0.025
5Y0.36910Y0.398-0.029

2. Market Valuation of Hubei Jumpcan Pharmaceutical Co Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ¥1 in earnings Jumpcan generates.

  • Above 15 is considered overpriced but always compare Jumpcan to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 8.24 means the investor is paying ¥8.24 for every ¥1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Hubei Jumpcan Pharmaceutical Co Ltd:

  • The EOD is 10.531. Based on the earnings, the company is underpriced. +1
  • The MRQ is 8.244. Based on the earnings, the company is underpriced. +1
  • The TTM is 9.617. Based on the earnings, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD10.531MRQ8.244+2.287
MRQ8.244TTM9.617-1.374
TTM9.617YOY11.212-1.595
TTM9.6175Y13.292-3.674
5Y13.29210Y21.858-8.566
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Hubei Jumpcan Pharmaceutical Co Ltd:

  • The EOD is 17.108. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 13.392. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 9.554. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD17.108MRQ13.392+3.716
MRQ13.392TTM9.554+3.838
TTM9.554YOY10.738-1.184
TTM9.5545Y14.607-5.053
5Y14.60710Y24.225-9.618
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Jumpcan is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Hubei Jumpcan Pharmaceutical Co Ltd:

  • The EOD is 2.768. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.167. Based on the equity, the company is underpriced. +1
  • The TTM is 2.155. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.768MRQ2.167+0.601
MRQ2.167TTM2.155+0.012
TTM2.155YOY2.355-0.200
TTM2.1555Y2.888-0.733
5Y2.88810Y5.813-2.925
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Hubei Jumpcan Pharmaceutical Co Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.9630.547+76%0.602+60%0.429+124%0.331+191%
Book Value Per Share--14.50313.498+7%11.046+31%9.527+52%6.586+120%
Current Ratio--3.1003.178-2%3.141-1%3.038+2%1.697+83%
Debt To Asset Ratio--0.2630.256+3%0.241+9%0.268-2%0.282-7%
Debt To Equity Ratio--0.3580.344+4%0.319+12%0.369-3%0.398-10%
Dividend Per Share--0.0110.223-95%0.164-93%0.209-95%0.249-96%
Eps--0.9530.765+25%0.589+62%0.521+83%0.398+140%
Free Cash Flow Per Share--0.5870.857-32%0.645-9%0.550+7%0.428+37%
Free Cash Flow To Equity Per Share--0.5870.815-28%0.613-4%0.481+22%0.428+37%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--39.296--------
Intrinsic Value_10Y_min--20.819--------
Intrinsic Value_1Y_max--2.796--------
Intrinsic Value_1Y_min--1.787--------
Intrinsic Value_3Y_max--9.271--------
Intrinsic Value_3Y_min--5.660--------
Intrinsic Value_5Y_max--16.795--------
Intrinsic Value_5Y_min--9.822--------
Market Cap37010550086.400+22%28972393255.68026805075105.820+8%23879513040.400+21%23494361614.972+23%25958678956.478+12%
Net Profit Margin--0.2820.294-4%0.249+13%0.242+16%0.222+27%
Operating Margin---0.146-100%0.257-100%0.227-100%0.133-100%
Operating Ratio--0.8740.884-1%0.910-4%0.919-5%0.581+50%
Pb Ratio2.768+22%2.1672.155+1%2.355-8%2.888-25%5.813-63%
Pe Ratio10.531+22%8.2449.617-14%11.212-26%13.292-38%21.858-62%
Price Per Share40.150+22%31.43029.073+8%25.905+21%25.486+23%28.160+12%
Price To Free Cash Flow Ratio17.108+22%13.3929.554+40%10.738+25%14.607-8%24.225-45%
Price To Total Gains Ratio41.235+22%32.28063.555-49%39.042-17%53.624-40%57.459-44%
Quick Ratio--1.2861.109+16%1.904-32%1.380-7%1.2900%
Return On Assets--0.0480.042+15%0.040+20%0.040+20%0.046+6%
Return On Equity--0.0660.057+16%0.053+23%0.055+19%0.064+2%
Total Gains Per Share--0.9740.770+26%0.767+27%0.638+53%0.580+68%
Usd Book Value--1844903026.0571717494238.924+7%1405192454.740+31%1211983095.255+52%837786281.899+120%
Usd Book Value Change Per Share--0.1330.075+76%0.083+60%0.059+124%0.046+191%
Usd Book Value Per Share--2.0011.863+7%1.524+31%1.315+52%0.909+120%
Usd Dividend Per Share--0.0020.031-95%0.023-93%0.029-95%0.034-96%
Usd Eps--0.1320.106+25%0.081+62%0.072+83%0.055+140%
Usd Free Cash Flow--74635653.311109099833.412-32%82012510.475-9%69957740.454+7%54447093.867+37%
Usd Free Cash Flow Per Share--0.0810.118-32%0.089-9%0.076+7%0.059+37%
Usd Free Cash Flow To Equity Per Share--0.0810.112-28%0.085-4%0.066+22%0.059+37%
Usd Market Cap5107455911.923+22%3998190269.2843699100364.603+8%3295372799.575+21%3242221902.866+23%3582297695.994+12%
Usd Price Per Share5.541+22%4.3374.012+8%3.575+21%3.517+23%3.886+12%
Usd Profit--121250008.63297385950.179+25%74891034.872+62%66328996.954+83%50592082.252+140%
Usd Revenue--430252568.801333081533.147+29%310374660.786+39%271766036.844+58%219657143.341+96%
Usd Total Gains Per Share--0.1340.106+26%0.106+27%0.088+53%0.080+68%
 EOD+4 -4MRQTTM+19 -16YOY+20 -155Y+29 -610Y+28 -7

3.2. Fundamental Score

Let's check the fundamental score of Hubei Jumpcan Pharmaceutical Co Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1510.531
Price to Book Ratio (EOD)Between0-12.768
Net Profit Margin (MRQ)Greater than00.282
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.286
Current Ratio (MRQ)Greater than13.100
Debt to Asset Ratio (MRQ)Less than10.263
Debt to Equity Ratio (MRQ)Less than10.358
Return on Equity (MRQ)Greater than0.150.066
Return on Assets (MRQ)Greater than0.050.048
Total6/10 (60.0%)

3.3. Technical Score

Let's check the technical score of Hubei Jumpcan Pharmaceutical Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.978
Ma 20Greater thanMa 5040.463
Ma 50Greater thanMa 10037.984
Ma 100Greater thanMa 20034.817
OpenGreater thanClose40.050
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in CNY. All numbers in thousands.

Summary
Total Assets18,143,695
Total Liabilities4,774,832
Total Stockholder Equity13,349,441
 As reported
Total Liabilities 4,774,832
Total Stockholder Equity+ 13,349,441
Total Assets = 18,143,695

Assets

Total Assets18,143,695
Total Current Assets14,235,430
Long-term Assets3,908,265
Total Current Assets
Cash And Cash Equivalents 7,737,983
Short-term Investments 3,178,270
Net Receivables 2,726,519
Inventory 490,078
Other Current Assets 6,879
Total Current Assets  (as reported)14,235,430
Total Current Assets  (calculated)14,139,730
+/- 95,700
Long-term Assets
Property Plant Equipment 2,922,473
Goodwill 167,304
Intangible Assets 315,697
Long-term Assets Other 56,262
Long-term Assets  (as reported)3,908,265
Long-term Assets  (calculated)3,461,735
+/- 446,529

Liabilities & Shareholders' Equity

Total Current Liabilities4,591,862
Long-term Liabilities182,970
Total Stockholder Equity13,349,441
Total Current Liabilities
Short Long Term Debt 1,043,077
Accounts payable 2,140,774
Other Current Liabilities 47,095
Total Current Liabilities  (as reported)4,591,862
Total Current Liabilities  (calculated)3,230,947
+/- 1,360,915
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt1,434
Long-term Liabilities  (as reported)182,970
Long-term Liabilities  (calculated)1,434
+/- 181,536
Total Stockholder Equity
Retained Earnings 8,847,776
Total Stockholder Equity (as reported)13,349,441
Total Stockholder Equity (calculated)8,847,776
+/- 4,501,665
Other
Capital Stock452,736
Common Stock Shares Outstanding 921,807
Net Invested Capital 14,392,519
Net Working Capital 9,643,568
Property Plant and Equipment Gross 2,922,473



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-06-302000-12-31
> Total Assets 
223,383
294,253
582,651
591,367
593,245
597,772
606,317
626,965
637,551
648,303
650,392
691,019
700,427
709,797
697,904
709,514
695,979
712,169
732,214
767,563
728,280
773,241
786,511
803,044
813,010
808,077
802,322
814,318
822,018
820,001
829,613
816,817
841,188
843,073
836,219
868,902
859,963
891,659
863,160
876,154
918,264
944,542
961,821
979,811
996,158
1,014,839
992,871
1,003,061
1,013,102
967,617
2,014,454
2,668,548
2,774,003
2,911,467
3,357,716
3,590,549
3,442,744
3,506,994
3,585,422
3,937,107
4,273,898
4,583,026
4,987,612
5,333,045
5,199,013
5,594,711
6,662,545
7,413,708
7,017,923
7,560,491
7,797,322
8,592,877
8,028,916
8,459,002
8,664,643
9,416,437
8,358,210
10,023,301
10,515,833
11,131,267
11,112,574
11,464,670
12,131,037
12,863,223
12,547,528
13,294,210
14,981,202
15,770,840
16,387,412
16,600,655
18,143,695
18,143,69516,600,65516,387,41215,770,84014,981,20213,294,21012,547,52812,863,22312,131,03711,464,67011,112,57411,131,26710,515,83310,023,3018,358,2109,416,4378,664,6438,459,0028,028,9168,592,8777,797,3227,560,4917,017,9237,413,7086,662,5455,594,7115,199,0135,333,0454,987,6124,583,0264,273,8983,937,1073,585,4223,506,9943,442,7443,590,5493,357,7162,911,4672,774,0032,668,5482,014,454967,6171,013,1021,003,061992,8711,014,839996,158979,811961,821944,542918,264876,154863,160891,659859,963868,902836,219843,073841,188816,817829,613820,001822,018814,318802,322808,077813,010803,044786,511773,241728,280767,563732,214712,169695,979709,514697,904709,797700,427691,019650,392648,303637,551626,965606,317597,772593,245591,367582,651294,253223,383
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,859,011
4,289,740
4,357,834
5,134,428
4,447,856
4,764,777
4,911,643
5,549,352
4,421,232
6,058,997
6,575,690
7,190,122
7,187,840
7,526,987
8,122,784
8,868,108
8,652,870
9,449,792
11,176,698
11,982,091
12,601,951
12,779,126
14,235,430
14,235,43012,779,12612,601,95111,982,09111,176,6989,449,7928,652,8708,868,1088,122,7847,526,9877,187,8407,190,1226,575,6906,058,9974,421,2325,549,3524,911,6434,764,7774,447,8565,134,4284,357,8344,289,7403,859,01100000000000000000000000000000000000000000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,058,896
1,422,955
1,586,901
2,094,214
1,446,593
2,038,405
2,284,815
2,887,843
2,321,623
3,857,176
2,959,157
3,650,828
3,731,502
4,085,297
3,818,996
2,878,736
2,513,589
3,080,300
4,818,941
7,467,759
8,243,546
7,676,029
7,737,983
7,737,9837,676,0298,243,5467,467,7594,818,9413,080,3002,513,5892,878,7363,818,9964,085,2973,731,5023,650,8282,959,1573,857,1762,321,6232,887,8432,284,8152,038,4051,446,5932,094,2141,586,9011,422,9551,058,89600000000000000000000000000000000000000000000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
398,000
0
288,000
0
259,000
0
190,000
175,000
100,000
76,000
1,257,990
1,205,000
1,170,000
1,170,000
1,675,000
3,505,000
3,750,000
3,816,000
3,044,552
1,683,730
1,588,335
2,443,865
3,178,270
3,178,2702,443,8651,588,3351,683,7303,044,5523,816,0003,750,0003,505,0001,675,0001,170,0001,170,0001,205,0001,257,99076,000100,000175,000190,0000259,0000288,0000398,00000000000000000000000000000000000000000000000000000000000000000000000
       Net Receivables 
40,750
56,988
51,507
80,855
70,032
65,308
48,211
63,102
71,911
75,166
70,681
113,763
115,681
122,896
105,481
126,211
114,682
115,436
111,079
123,654
110,557
110,720
145,170
150,440
177,727
195,116
177,118
179,553
191,928
178,930
171,233
167,499
182,698
191,730
171,775
196,118
186,505
196,033
167,171
171,686
181,504
179,107
210,404
221,462
213,493
228,638
162,338
189,648
167,862
160,448
771,993
821,104
928,683
931,024
918,137
1,023,140
1,141,954
1,153,846
1,135,825
1,267,310
1,365,950
1,416,521
1,434,352
1,598,096
1,734,596
1,817,607
1,814,816
2,222,051
2,153,334
2,201,595
2,116,713
2,258,422
2,261,568
1,968,969
2,065,352
2,159,117
1,641,676
1,847,094
2,041,986
2,020,311
2,006,016
1,917,441
2,194,856
2,027,912
1,894,493
2,068,942
2,867,497
2,285,228
2,193,786
2,013,103
2,726,519
2,726,5192,013,1032,193,7862,285,2282,867,4972,068,9421,894,4932,027,9122,194,8561,917,4412,006,0162,020,3112,041,9861,847,0941,641,6762,159,1172,065,3521,968,9692,261,5682,258,4222,116,7132,201,5952,153,3342,222,0511,814,8161,817,6071,734,5961,598,0961,434,3521,416,5211,365,9501,267,3101,135,8251,153,8461,141,9541,023,140918,137931,024928,683821,104771,993160,448167,862189,648162,338228,638213,493221,462210,404179,107181,504171,686167,171196,033186,505196,118171,775191,730182,698167,499171,233178,930191,928179,553177,118195,116177,727150,440145,170110,720110,557123,654111,079115,436114,682126,211105,481122,896115,681113,76370,68175,16671,91163,10248,21165,30870,03280,85551,50756,98840,750
       Other Current Assets 
4,609
7,952
2,032
4,714
4,167
2,333
2,896
6,270
8,416
8,034
5,404
4,846
12,316
14,355
7,051
7,355
6,921
943
1,693
1,709
1,839
2,037
6,996
12,567
4,391
6,401
13,550
27,289
20,905
21,230
27,275
28,150
41,709
34,866
40,386
10,848
8,292
9,876
10,753
10,324
15,037
12,550
14,314
13,200
14,307
13,300
18,321
16,167
20,910
7,695
11,828
12,075
11,989
9,149
11,308
246,589
12,828
181,596
10,836
144,538
16,058
253,511
21,956
182,449
48,630
174,743
32,672
586,792
44,338
428,651
47,885
275,454
267,539
231,948
33,003
42,559
36,988
33,521
38,133
30,188
38,859
47,988
58,343
49,733
45,431
44,951
54,232
47,645
45,111
8,035
6,879
6,8798,03545,11147,64554,23244,95145,43149,73358,34347,98838,85930,18838,13333,52136,98842,55933,003231,948267,539275,45447,885428,65144,338586,79232,672174,74348,630182,44921,956253,51116,058144,53810,836181,59612,828246,58911,3089,14911,98912,07511,8287,69520,91016,16718,32113,30014,30713,20014,31412,55015,03710,32410,7539,8768,29210,84840,38634,86641,70928,15027,27521,23020,90527,28913,5506,4014,39112,5676,9962,0371,8391,7091,6939436,9217,3557,05114,35512,3164,8465,4048,0348,4166,2702,8962,3334,1674,7142,0327,9524,609
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,458,450
3,581,060
3,694,225
3,753,001
3,867,085
3,936,977
3,964,304
3,940,142
3,941,145
3,924,733
3,937,684
4,008,252
3,995,114
3,894,658
3,844,419
3,804,505
3,788,750
3,785,461
3,821,529
3,908,265
3,908,2653,821,5293,785,4613,788,7503,804,5053,844,4193,894,6583,995,1144,008,2523,937,6843,924,7333,941,1453,940,1423,964,3043,936,9773,867,0853,753,0013,694,2253,581,0603,458,45000000000000000000000000000000000000000000000000000000000000000000000000
       Property Plant Equipment 
102,679
125,121
185,555
184,583
216,506
223,189
248,551
256,353
263,465
265,694
280,453
279,358
297,786
301,300
336,278
336,737
450,545
370,930
461,307
384,520
479,389
414,967
488,205
254,991
281,183
231,263
253,122
235,478
260,892
231,953
249,828
245,377
253,375
231,656
242,406
266,923
250,309
243,784
256,972
239,048
288,194
287,815
292,254
283,839
307,743
285,708
321,563
306,514
319,380
245,109
1,003,282
883,382
897,204
1,010,068
1,052,586
1,168,214
1,251,775
1,288,488
1,354,257
1,414,922
1,457,184
1,561,416
1,692,440
1,724,495
1,824,812
2,102,304
2,320,303
2,378,926
2,471,103
2,552,002
2,814,247
2,775,576
2,835,269
2,925,029
3,018,029
3,115,077
3,171,632
3,173,762
3,140,879
3,109,521
3,084,004
3,068,416
3,034,005
2,976,109
2,924,898
2,874,028
2,856,070
2,848,321
2,880,375
2,861,613
2,922,473
2,922,4732,861,6132,880,3752,848,3212,856,0702,874,0282,924,8982,976,1093,034,0053,068,4163,084,0043,109,5213,140,8793,173,7623,171,6323,115,0773,018,0292,925,0292,835,2692,775,5762,814,2472,552,0022,471,1032,378,9262,320,3032,102,3041,824,8121,724,4951,692,4401,561,4161,457,1841,414,9221,354,2571,288,4881,251,7751,168,2141,052,5861,010,068897,204883,3821,003,282245,109319,380306,514321,563285,708307,743283,839292,254287,815288,194239,048256,972243,784250,309266,923242,406231,656253,375245,377249,828231,953260,892235,478253,122231,263281,183254,991488,205414,967479,389384,520461,307370,930450,545336,737336,278301,300297,786279,358280,453265,694263,465256,353248,551223,189216,506184,583185,555125,121102,679
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
192,877
192,877
192,877
167,304
167,304
167,304
167,304
167,304
167,304
167,304
167,304
167,304
167,304
167,304
167,304
167,304
167,304
167,304
167,304
167,304
167,304
167,304
167,304
167,304
167,304
167,304
167,304
167,304
167,304
167,304
167,304
167,304
167,304
167,304
167,304
167,304
167,304167,304167,304167,304167,304167,304167,304167,304167,304167,304167,304167,304167,304167,304167,304167,304167,304167,304167,304167,304167,304167,304167,304167,304167,304167,304167,304167,304167,304167,304167,304167,304167,304192,877192,877192,8770000000000000000000000000000000000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
55,216
61,012
62,235
61,807
127,190
134,423
106,620
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000106,620134,423127,19061,80762,23561,01255,21600000000000000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
29,782
29,459
30,452
30,290
30,393
72,005
71,495
71,063
70,632
70,201
69,584
69,134
68,673
68,213
69,172
68,704
68,266
67,798
67,232
66,747
66,262
65,777
65,291
28,585
28,407
28,230
28,053
27,875
27,698
27,521
27,344
27,166
26,989
26,812
930
27,387
930
27,033
837
26,577
791
26,161
744
25,760
698
25,359
651
24,957
605
19,593
1,322
131,213
141,064
142,770
141,342
373,266
370,161
368,544
377,084
372,472
393,536
395,078
392,947
388,068
384,396
380,331
389,899
385,436
213,970
291,976
321,280
315,314
51,415
315,685
335,835
332,383
328,482
327,360
283,838
288,060
285,463
281,087
280,038
275,819
304,760
299,671
320,623
314,649
308,808
303,927
315,697
315,697303,927308,808314,649320,623299,671304,760275,819280,038281,087285,463288,060283,838327,360328,482332,383335,835315,68551,415315,314321,280291,976213,970385,436389,899380,331384,396388,068392,947395,078393,536372,472377,084368,544370,161373,266141,342142,770141,064131,2131,32219,59360524,95765125,35969825,76074426,16179126,57783727,03393027,38793026,81226,98927,16627,34427,52127,69827,87528,05328,23028,40728,58565,29165,77766,26266,74767,23267,79868,26668,70469,17268,21368,67369,13469,58470,20170,63271,06371,49572,00530,39330,29030,45229,45929,782
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
46,808
166,358
62,688
31,564
30,879
32,533
3,212,095
76,789
74,784
77,810
69,653
78,564
121,870
26,003
30,027
15,158
10,540
22,196
65,440
56,262
56,26265,44022,19610,54015,15830,02726,003121,87078,56469,65377,81074,78476,7893,212,09532,53330,87931,56462,688166,35846,80800000000000000000000000000000000000000000000000000000000000000000000000
> Total Liabilities 
83,375
143,213
133,078
136,491
134,815
134,466
148,168
164,671
170,309
178,510
183,918
223,650
229,004
235,540
223,980
234,988
218,524
232,573
251,960
286,667
243,825
287,378
300,694
313,540
318,702
312,089
303,495
315,106
319,366
316,448
323,430
310,160
332,695
332,088
323,368
355,466
344,362
372,331
342,889
355,080
396,004
417,409
434,996
452,079
468,781
484,801
502,072
512,075
540,140
476,369
862,042
768,333
744,275
758,152
1,063,721
1,413,297
1,094,471
990,930
872,592
1,015,535
1,080,703
1,154,113
1,300,104
1,434,341
1,600,234
1,670,427
2,260,734
2,545,063
2,422,667
2,481,770
2,339,501
2,621,533
2,569,214
2,657,371
2,560,213
2,847,746
2,571,307
2,577,788
2,752,651
2,928,967
2,895,246
2,779,676
2,999,988
3,150,635
3,004,303
3,172,332
3,628,677
3,736,594
4,492,000
4,116,734
4,774,832
4,774,8324,116,7344,492,0003,736,5943,628,6773,172,3323,004,3033,150,6352,999,9882,779,6762,895,2462,928,9672,752,6512,577,7882,571,3072,847,7462,560,2132,657,3712,569,2142,621,5332,339,5012,481,7702,422,6672,545,0632,260,7341,670,4271,600,2341,434,3411,300,1041,154,1131,080,7031,015,535872,592990,9301,094,4711,413,2971,063,721758,152744,275768,333862,042476,369540,140512,075502,072484,801468,781452,079434,996417,409396,004355,080342,889372,331344,362355,466323,368332,088332,695310,160323,430316,448319,366315,106303,495312,089318,702313,540300,694287,378243,825286,667251,960232,573218,524234,988223,980235,540229,004223,650183,918178,510170,309164,671148,168134,466134,815136,491133,078143,21383,375
   > Total Current Liabilities 
73,707
79,989
72,053
75,467
73,790
73,442
88,168
104,670
106,709
114,910
119,919
159,529
164,984
171,520
165,381
176,008
159,923
173,973
228,360
233,067
190,226
237,377
250,694
263,540
268,702
262,089
253,495
265,106
269,366
266,448
273,430
260,160
282,696
282,088
293,368
325,466
344,362
372,331
328,889
319,900
315,824
307,229
326,081
328,164
344,866
363,417
379,422
389,425
418,122
354,668
833,509
740,437
717,024
731,544
1,035,592
1,386,014
1,067,992
965,274
840,264
984,195
1,024,532
1,098,220
1,234,375
1,368,778
1,520,547
1,551,132
1,491,581
1,762,629
1,787,579
1,844,561
1,667,808
1,944,335
1,866,095
1,934,885
1,839,907
2,112,109
1,822,398
1,785,084
1,967,010
2,133,037
2,092,824
1,960,817
2,800,600
2,945,442
2,791,928
2,957,906
3,427,283
3,527,697
4,281,858
3,905,300
4,591,862
4,591,8623,905,3004,281,8583,527,6973,427,2832,957,9062,791,9282,945,4422,800,6001,960,8172,092,8242,133,0371,967,0101,785,0841,822,3982,112,1091,839,9071,934,8851,866,0951,944,3351,667,8081,844,5611,787,5791,762,6291,491,5811,551,1321,520,5471,368,7781,234,3751,098,2201,024,532984,195840,264965,2741,067,9921,386,0141,035,592731,544717,024740,437833,509354,668418,122389,425379,422363,417344,866328,164326,081307,229315,824319,900328,889372,331344,362325,466293,368282,088282,696260,160273,430266,448269,366265,106253,495262,089268,702263,540250,694237,377190,226233,067228,360173,973159,923176,008165,381171,520164,984159,529119,919114,910106,709104,67088,16873,44273,79075,46772,05379,98973,707
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
664
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000066400000000000000000000000000000000000000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
664
0
0
0
0
0
0
0
0
0
0
0
400,000
400,000
551,356
801,646
1,043,077
1,043,077801,646551,356400,000400,0000000000000066400000000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
22,728
27,515
14,979
16,602
24,216
14,075
22,044
16,003
18,531
20,384
19,547
28,681
29,772
36,541
27,873
43,359
35,042
38,033
57,007
62,978
61,371
57,319
54,013
62,465
63,387
59,999
65,872
74,935
66,387
60,618
74,337
76,049
81,449
72,824
58,215
66,827
52,510
68,129
59,884
65,136
69,947
61,956
71,337
83,954
86,369
79,198
87,249
92,555
80,369
62,211
170,060
175,976
191,725
199,003
224,577
250,654
259,852
265,702
218,981
239,757
164,345
324,142
305,396
460,964
364,707
530,901
356,636
493,862
357,743
550,617
385,282
612,660
582,232
640,009
436,087
832,994
477,405
697,861
452,518
817,489
502,918
775,889
705,386
901,590
735,780
820,210
1,348,545
1,917,380
2,023,379
1,876,004
2,140,774
2,140,7741,876,0042,023,3791,917,3801,348,545820,210735,780901,590705,386775,889502,918817,489452,518697,861477,405832,994436,087640,009582,232612,660385,282550,617357,743493,862356,636530,901364,707460,964305,396324,142164,345239,757218,981265,702259,852250,654224,577199,003191,725175,976170,06062,21180,36992,55587,24979,19886,36983,95471,33761,95669,94765,13659,88468,12952,51066,82758,21572,82481,44976,04974,33760,61866,38774,93565,87259,99963,38762,46554,01357,31961,37162,97857,00738,03335,04243,35927,87336,54129,77228,68119,54720,38418,53116,00322,04414,07524,21616,60214,97927,51522,728
       Other Current Liabilities 
21,802
21,950
28,360
30,151
20,960
30,753
18,657
21,200
18,111
24,459
30,305
30,781
35,145
34,912
32,441
29,582
32,881
33,940
39,853
38,589
32,355
33,558
50,181
54,575
58,815
45,590
41,623
44,171
56,979
59,830
53,593
45,911
55,747
58,844
54,733
63,719
56,932
69,282
54,085
63,844
55,157
55,053
64,524
57,990
70,477
96,199
94,653
89,350
130,453
85,157
403,449
473,462
476,300
532,542
531,015
895,361
658,140
699,571
621,283
744,437
860,187
774,078
928,979
907,814
1,155,841
1,020,231
1,134,945
1,268,767
1,236,369
1,169,256
1,078,014
1,234,770
1,332,182
1,178,672
1,212,384
1,184,718
1,226,640
978,138
1,305,507
1,217,481
1,404,216
1,053,026
1,223,414
1,304,054
1,233,393
1,375,717
1,327,907
1,125,904
1,496,301
37,556
47,095
47,09537,5561,496,3011,125,9041,327,9071,375,7171,233,3931,304,0541,223,4141,053,0261,404,2161,217,4811,305,507978,1381,226,6401,184,7181,212,3841,178,6721,332,1821,234,7701,078,0141,169,2561,236,3691,268,7671,134,9451,020,2311,155,841907,814928,979774,078860,187744,437621,283699,571658,140895,361531,015532,542476,300473,462403,44985,157130,45389,35094,65396,19970,47757,99064,52455,05355,15763,84454,08569,28256,93263,71954,73358,84455,74745,91153,59359,83056,97944,17141,62345,59058,81554,57550,18133,55832,35538,58939,85333,94032,88129,58232,44134,91235,14530,78130,30524,45918,11121,20018,65730,75320,96030,15128,36021,95021,802
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
677,198
703,119
722,487
720,306
735,637
748,909
792,705
785,641
795,930
802,422
818,859
199,388
205,193
212,375
214,426
201,394
208,897
210,142
211,434
182,970
182,970211,434210,142208,897201,394214,426212,375205,193199,388818,859802,422795,930785,641792,705748,909735,637720,306722,487703,119677,19800000000000000000000000000000000000000000000000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-664
0
0
0
0
1,811
1,537
2,053
1,016
756
581
409
202
1,042
950
952
1,434
1,4349529501,0422024095817561,0162,0531,5371,8110000-66400000000000000000000000000000000000000000000000000000000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
555,989
562,349
569,308
576,150
582,695
589,414
2,859
0
1,654
0
1,599
0
1,297
0
0
0
0
0
0
0
00000001,29701,59901,65402,859589,414582,695576,150569,308562,349555,98900000000000000000000000000000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,209
2,643
2,077
1,510
944
2,361
4,411
7,174
20,314
21,849
23,666
21,063
18,461
15,729
13,192
10,652
8,551
6,442
3,870
1,964
876
0
0
008761,9643,8706,4428,55110,65213,19215,72918,46121,06323,66621,84920,3147,1744,4112,3619441,5102,0772,6433,20900000000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
140,008
151,039
449,573
454,876
458,431
463,306
458,150
461,393
466,333
468,849
465,552
466,435
470,480
473,311
472,980
473,568
476,493
478,634
479,285
479,925
483,478
484,886
484,839
488,521
493,305
494,982
497,822
498,206
501,642
502,538
505,138
505,609
507,445
509,935
511,784
512,368
514,532
518,256
519,183
519,984
521,168
526,033
525,718
526,621
526,267
528,919
489,683
489,869
471,853
490,142
1,152,413
1,900,215
2,029,728
2,153,315
2,293,995
2,141,042
2,312,613
2,480,415
2,667,984
2,877,108
3,163,454
3,399,197
3,657,338
3,898,704
3,598,779
3,924,284
4,401,811
4,868,644
4,595,256
5,078,721
5,457,821
5,971,344
5,459,702
5,801,631
6,104,430
6,568,691
5,786,903
7,445,513
7,763,181
8,202,300
8,217,328
8,669,349
9,116,878
9,698,141
9,528,627
10,106,492
11,337,386
12,017,707
11,878,059
12,465,559
13,349,441
13,349,44112,465,55911,878,05912,017,70711,337,38610,106,4929,528,6279,698,1419,116,8788,669,3498,217,3288,202,3007,763,1817,445,5135,786,9036,568,6916,104,4305,801,6315,459,7025,971,3445,457,8215,078,7214,595,2564,868,6444,401,8113,924,2843,598,7793,898,7043,657,3383,399,1973,163,4542,877,1082,667,9842,480,4152,312,6132,141,0422,293,9952,153,3152,029,7281,900,2151,152,413490,142471,853489,869489,683528,919526,267526,621525,718526,033521,168519,984519,183518,256514,532512,368511,784509,935507,445505,609505,138502,538501,642498,206497,822494,982493,305488,521484,839484,886483,478479,925479,285478,634476,493473,568472,980473,311470,480466,435465,552468,849466,333461,393458,150463,306458,431454,876449,573151,039140,008
   Common Stock
66,308
66,308
106,308
106,308
106,308
106,308
106,308
106,308
106,308
106,308
106,308
106,308
106,308
106,308
106,308
106,308
106,308
106,308
106,308
106,308
106,308
106,308
106,308
106,308
106,308
106,308
106,308
106,308
106,308
106,308
106,308
106,308
106,308
106,308
106,308
106,308
138,200
138,200
138,200
138,200
138,200
138,200
138,200
138,200
138,200
138,200
138,200
138,200
138,200
138,200
367,876
383,803
383,803
383,803
383,803
383,803
383,803
383,803
383,803
383,803
397,638
397,638
397,638
397,638
397,638
397,638
397,638
397,638
399,952
400,189
400,189
400,234
400,240
400,241
400,241
400,242
400,242
473,573
436,258
436,258
436,259
436,259
436,266
436,268
436,270
439,256
452,743
452,743
453,036
0
0
00453,036452,743452,743439,256436,270436,268436,266436,259436,259436,258436,258473,573400,242400,242400,241400,241400,240400,234400,189400,189399,952397,638397,638397,638397,638397,638397,638397,638397,638383,803383,803383,803383,803383,803383,803383,803383,803383,803367,876138,200138,200138,200138,200138,200138,200138,200138,200138,200138,200138,200138,200138,200138,200106,308106,308106,308106,308106,308106,308106,308106,308106,308106,308106,308106,308106,308106,308106,308106,308106,308106,308106,308106,308106,308106,308106,308106,308106,308106,308106,308106,308106,308106,308106,308106,308106,308106,30866,30866,308
   Retained Earnings 
31,401
42,432
35,816
41,119
44,674
49,550
42,309
45,552
50,493
53,009
48,613
49,495
53,540
56,372
54,918
55,506
58,431
60,572
59,956
60,595
64,149
65,557
65,872
69,554
74,337
76,015
77,885
78,268
81,704
82,601
84,560
85,030
86,866
89,356
90,539
91,123
93,288
97,011
97,195
97,995
99,180
104,044
103,032
103,935
103,581
106,233
66,997
67,183
49,167
67,456
363,982
528,728
658,241
781,828
922,508
769,555
941,126
1,108,928
1,296,497
1,505,621
1,189,778
1,425,521
1,683,662
1,974,373
1,674,447
1,999,953
2,316,100
2,782,933
2,348,882
2,815,133
3,194,228
3,542,579
3,030,467
3,372,383
3,837,006
4,301,179
3,519,390
3,794,192
4,111,860
4,550,979
4,565,989
4,984,115
5,431,320
6,012,509
5,842,859
6,419,403
6,998,045
7,674,801
7,526,778
7,969,266
8,847,776
8,847,7767,969,2667,526,7787,674,8016,998,0456,419,4035,842,8596,012,5095,431,3204,984,1154,565,9894,550,9794,111,8603,794,1923,519,3904,301,1793,837,0063,372,3833,030,4673,542,5793,194,2282,815,1332,348,8822,782,9332,316,1001,999,9531,674,4471,974,3731,683,6621,425,5211,189,7781,505,6211,296,4971,108,928941,126769,555922,508781,828658,241528,728363,98267,45649,16767,18366,997106,233103,581103,935103,032104,04499,18097,99597,19597,01193,28891,12390,53989,35686,86685,03084,56082,60181,70478,26877,88576,01574,33769,55465,87265,55764,14960,59559,95660,57258,43155,50654,91856,37253,54049,49548,61353,00950,49345,55242,30949,55044,67441,11935,81642,43231,401
   Capital Surplus 0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
104,652
101,567
101,566
100,979
100,897
100,895
100,895
100,880
100,880
100,874
100,873
100,873
100,871
100,867
100,814
100,803
100,781
100,761
0
0
0
0
0
00000100,761100,781100,803100,814100,867100,871100,873100,873100,874100,880100,880100,895100,895100,897100,979101,566101,567104,65200000000000000000000000000000000000000000000000000000000000000000000



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue9,654,537
Cost of Revenue-1,783,993
Gross Profit7,870,5447,870,544
 
Operating Income (+$)
Gross Profit7,870,544
Operating Expense-6,753,574
Operating Income2,900,9631,116,970
 
Operating Expense (+$)
Research Development464,400
Selling General Administrative4,089,734
Selling And Marketing Expenses0
Operating Expense6,753,5744,554,134
 
Net Interest Income (+$)
Interest Income276,084
Interest Expense-17,584
Other Finance Cost-1,011
Net Interest Income257,489
 
Pretax Income (+$)
Operating Income2,900,963
Net Interest Income257,489
Other Non-Operating Income Expenses0
Income Before Tax (EBT)3,297,0902,900,963
EBIT - interestExpense = -17,584
2,822,781
2,840,365
Interest Expense17,584
Earnings Before Interest and Taxes (EBIT)03,314,674
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax3,297,090
Tax Provision-470,027
Net Income From Continuing Ops2,827,0632,827,063
Net Income2,822,781
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-257,489
 

Technical Analysis of Jumpcan
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Jumpcan. The general trend of Jumpcan is BULLISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Jumpcan's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (85.7%) Bearish trend (-85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Hubei Jumpcan Pharmaceutical Co Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 45.18.

The bearish price targets are: 39.32 > 35.13 > 34.50.

Tweet this
Hubei Jumpcan Pharmaceutical Co Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Hubei Jumpcan Pharmaceutical Co Ltd. The current mas is .

The long score for the Moving Averages is 13/14.
The longshort score for the Moving Averages is 12/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Hubei Jumpcan Pharmaceutical Co Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Hubei Jumpcan Pharmaceutical Co Ltd. The current macd is 1.16791712.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Jumpcan price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Jumpcan. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Jumpcan price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Hubei Jumpcan Pharmaceutical Co Ltd Daily Moving Average Convergence/Divergence (MACD) ChartHubei Jumpcan Pharmaceutical Co Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Hubei Jumpcan Pharmaceutical Co Ltd. The current adx is 31.47.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Jumpcan shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Hubei Jumpcan Pharmaceutical Co Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Hubei Jumpcan Pharmaceutical Co Ltd. The current sar is 44.35.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Hubei Jumpcan Pharmaceutical Co Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Hubei Jumpcan Pharmaceutical Co Ltd. The current rsi is 51.98. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
Hubei Jumpcan Pharmaceutical Co Ltd Daily Relative Strength Index (RSI) ChartHubei Jumpcan Pharmaceutical Co Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Hubei Jumpcan Pharmaceutical Co Ltd. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Jumpcan price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Hubei Jumpcan Pharmaceutical Co Ltd Daily Stochastic Oscillator ChartHubei Jumpcan Pharmaceutical Co Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Hubei Jumpcan Pharmaceutical Co Ltd. The current cci is -7.53860411.

Hubei Jumpcan Pharmaceutical Co Ltd Daily Commodity Channel Index (CCI) ChartHubei Jumpcan Pharmaceutical Co Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Hubei Jumpcan Pharmaceutical Co Ltd. The current cmo is -12.04058592.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Hubei Jumpcan Pharmaceutical Co Ltd Daily Chande Momentum Oscillator (CMO) ChartHubei Jumpcan Pharmaceutical Co Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Hubei Jumpcan Pharmaceutical Co Ltd. The current willr is -61.19221411.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Jumpcan is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Hubei Jumpcan Pharmaceutical Co Ltd Daily Williams %R ChartHubei Jumpcan Pharmaceutical Co Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Hubei Jumpcan Pharmaceutical Co Ltd.

Hubei Jumpcan Pharmaceutical Co Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Hubei Jumpcan Pharmaceutical Co Ltd. The current atr is 1.43767868.

Hubei Jumpcan Pharmaceutical Co Ltd Daily Average True Range (ATR) ChartHubei Jumpcan Pharmaceutical Co Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Hubei Jumpcan Pharmaceutical Co Ltd. The current obv is 255,601,994.

Hubei Jumpcan Pharmaceutical Co Ltd Daily On-Balance Volume (OBV) ChartHubei Jumpcan Pharmaceutical Co Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Hubei Jumpcan Pharmaceutical Co Ltd. The current mfi is 53.15.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Hubei Jumpcan Pharmaceutical Co Ltd Daily Money Flow Index (MFI) ChartHubei Jumpcan Pharmaceutical Co Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Hubei Jumpcan Pharmaceutical Co Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-01RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-26CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-31WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-07CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-03-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-01WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-11ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-19MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

Hubei Jumpcan Pharmaceutical Co Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Hubei Jumpcan Pharmaceutical Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.978
Ma 20Greater thanMa 5040.463
Ma 50Greater thanMa 10037.984
Ma 100Greater thanMa 20034.817
OpenGreater thanClose40.050
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Jumpcan with someone you think should read this too:
  • Are you bullish or bearish on Jumpcan? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Jumpcan? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Hubei Jumpcan Pharmaceutical Co Ltd

I send you an email if I find something interesting about Hubei Jumpcan Pharmaceutical Co Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Hubei Jumpcan Pharmaceutical Co Ltd.

Receive notifications about Hubei Jumpcan Pharmaceutical Co Ltd in your mailbox!